Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

Abstract Introduction The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinical outcomes. However, mAbs, such as rituximab, natalizumab, and ocrel...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi, Yazed AlRuthia
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2023-05-01
سلاسل:	BMC Health Services Research
الموضوعات:	Multiple sclerosis Relapsing-remitting Natalizumab Rituximab Ocrelizumab Cost effectiveness
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12913-023-09462-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!